ADO 8.70% 2.1¢ anteotech ltd

ADO Charting and Technical Analysis, page-2098

  1. 5,184 Posts.
    lightbulb Created with Sketch. 1681
    Merck shares MRK, +0.03% jumped 3.5% in premarket trade Friday, after the company said the oral antiviral it developed as a treatment for COVID-19 with partner Ridgeback Biotherapeutics reduced the risk of hospitalization or death in at risk adult patients with mild-to-moderate COVID by about 50% in an interim analysis of data from a Phase 3 trial. Some 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of patients given a placebo. Through Day 29, no patients given molnupiravir died, compared with eight patients who died on placebo. The company is now planning to submit an application for an emergency use authorization for the treatment from the Food and Drug Administration and will also seek it from other regulatory bodies around the world. The interim analysis looked at data from 775 patients enrolled in the trial on or prior to Aug. 5. Merck is planning to produce 10 million courses of treatment by year-end with more to come in 2022. Shares have fallen 3.7% in the year to date, while the S&P 500 SPX, -1.19% has gained 14.7%.

    Combine that with double vaccination and booster shots and our current management of COVID in OZ is history.

    all IMO
 
watchlist Created with Sketch. Add ADO (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
-0.002(8.70%)
Mkt cap ! $52.28M
Open High Low Value Volume
2.2¢ 2.2¢ 2.1¢ $20.83K 964.6K

Buyers (Bids)

No. Vol. Price($)
4 2247357 2.1¢
 

Sellers (Offers)

Price($) Vol. No.
2.2¢ 164375 3
View Market Depth
Last trade - 16.10pm 04/10/2024 (20 minute delay) ?
ADO (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.